Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The KMT2A recombinome of acute leukemias in 2023.
Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gröger D, Sutton R, Venn NC, Cazzaniga G, Corral Abascal L, Tsaur G, Fechina L, Emerenciano M, Pombo-de-Oliveira MS, Lund-Aho T, Lundán T, Montonen M, Juvonen V, Zuna J, Trka J, Ballerini P, Lapillonne H, Van der Velden VHJ, Sonneveld E, Delabesse E, de Matos RRC, Silva MLM, Bomken S, Katsibardi K, Keernik M, Grardel N, Mason J, Price R, Kim J, Eckert C, Lo Nigro L, Bueno C, Menendez P, Zur Stadt U, Gameiro P, Sedék L, Szczepański T, Bidet A, Marcu V, Shichrur K, Izraeli S, Madsen HO, Schäfer BW, Kubetzko S, Kim R, Clappier E, Trautmann H, Brüggemann M, Archer P, Hancock J, Alten J, Möricke A, Stanulla M, Lentes J, Bergmann AK, Strehl S, Köhrer S, Nebral K, Dworzak MN, Haas OA, Arfeuille C, Caye-Eude A, Cavé H, Marschalek R. Meyer C, et al. Among authors: caye eude a. Leukemia. 2023 May;37(5):988-1005. doi: 10.1038/s41375-023-01877-1. Epub 2023 Apr 5. Leukemia. 2023. PMID: 37019990 Free PMC article.
Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions.
Meyer C, Lopes BA, Caye-Eude A, Cavé H, Arfeuille C, Cuccuini W, Sutton R, Venn NC, Oh SH, Tsaur G, Escherich G, Feuchtinger T, Kosasih HJ, Khaw SL, Ekert PG, Pombo-de-Oliveira MS, Bidet A, Djahanschiri B, Ebersberger I, Zaliova M, Zuna J, Zermanova Z, Juvonen V, Grümayer RP, Fazio G, Cazzaniga G, Larghero P, Emerenciano M, Marschalek R. Meyer C, et al. Leukemia. 2019 Sep;33(9):2306-2340. doi: 10.1038/s41375-019-0451-7. Epub 2019 Mar 21. Leukemia. 2019. PMID: 30899083 Free PMC article. No abstract available.
B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.
Fournier B, Balducci E, Duployez N, Clappier E, Cuccuini W, Arfeuille C, Caye-Eude A, Delabesse E, Bottollier-Lemallaz Colomb E, Nebral K, Chrétien ML, Derrieux C, Cabannes-Hamy A, Dumezy F, Etancelin P, Fenneteau O, Frayfer J, Gourmel A, Loosveld M, Michel G, Nadal N, Penther D, Tigaud I, Fournier E, Reismüller B, Attarbaschi A, Lafage-Pochitaloff M, Baruchel A. Fournier B, et al. Front Oncol. 2019 Dec 10;9:1374. doi: 10.3389/fonc.2019.01374. eCollection 2019. Front Oncol. 2019. PMID: 31921638 Free PMC article.
Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia.
Chevillon F, Clappier E, Arfeuille C, Cayuela JM, Dalle JH, Kim R, Caye-Eude A, Chalas C, Abdo C, Drouineaud V, Peffault de Latour R, Alcantara M, Uzunov M, Degaud M, Meignin V, Dombret H, Boissel N, Poirot C, Dhédin N. Chevillon F, et al. Blood. 2021 Mar 25;137(12):1697-1701. doi: 10.1182/blood.2020007782. Blood. 2021. PMID: 33171484 Free article. No abstract available.
Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia.
Brethon B, Lainey E, Caye-Eude A, Grain A, Fenneteau O, Yakouben K, Roupret-Serzec J, Le Mouel L, Cavé H, Baruchel A. Brethon B, et al. Front Oncol. 2021 Feb 26;11:637951. doi: 10.3389/fonc.2021.637951. eCollection 2021. Front Oncol. 2021. PMID: 33718232 Free PMC article.
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.
Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, Méchinaud F, Grain A, Chaillou D, Rahal I, Caillat-Zucman S, Lesprit E, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guérin-El Khourouj V, Lainey E, Caye-Eude A, Cavé H, Clappier E, Mathis S, Azoulay E, Dalle JH, Dhédin N, Madelaine I, Larghero J, Boissel N, Baruchel A. Dourthe ME, et al. Leukemia. 2021 Dec;35(12):3383-3393. doi: 10.1038/s41375-021-01281-7. Epub 2021 May 17. Leukemia. 2021. PMID: 34002027
KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints.
Bataller A, Guijarro F, Caye-Eude A, Strullu M, Sterin A, Molina O, Chevallier P, Zaliova M, Zuna J, Mozas P, Magnano L, Grardel N, Cornillet-Lefebvre P, Fu JF, Shih LY, Boneva T, Nacheva E, Beà S, López-Guerra M, Bueno C, Menéndez P, Esteve J, Larghero P, Meyer C, Marschalek R. Bataller A, et al. Blood Adv. 2021 Dec 28;5(24):5617-5620. doi: 10.1182/bloodadvances.2021005736. Blood Adv. 2021. PMID: 34638131 Free PMC article. No abstract available.
The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.
Külp M, Siemund AL, Larghero P, Dietz A, Alten J, Cario G, Eckert C, Caye-Eude A, Cavé H, Bardini M, Cazzaniga G, De Lorenzo P, Valsecchi MG, Diehl L, Bonig H, Meyer C, Marschalek R. Külp M, et al. iScience. 2022 Jun 16;25(7):104613. doi: 10.1016/j.isci.2022.104613. eCollection 2022 Jul 15. iScience. 2022. PMID: 35800767 Free PMC article.
21 results